DMart Launches Aggressive Pharmacy Push: 20% Medicine Discount Tests Grocery Giant's Expansion Limits

DMart Launches Aggressive Pharmacy Push: 20% Medicine Discount Tests Grocery Giant's Expansion Limits​

DMart, the supermarket behemoth led by Radhakishan Damani, is quietly launching a high-stakes foray into healthcare retail. The company has introduced pharmacy counters within select stores in the Mumbai Metropolitan Region (MMR), signaling its attempt to replicate its successful everyday-low-pricing model across the pharmaceutical sector.

This strategic pivot aims to diversify DMart's business footprint beyond groceries and general merchandise. The initiative is managed by Reflect Healthcare and Retail Private Limited (RHRPL), a wholly owned subsidiary of Avenue Supermarts, with veteran Hitesh Shah spearheading the venture.

Adopting the "Shop-in-Shop" Playbook​

DMart has chosen a highly efficient and capital-light method for entry, eschewing expensive standalone storefronts. Instead, it is integrating dedicated pharmacy counters—a "shop-in-shop" model—into its existing brick-and-mortar hypermarkets. This approach allows the company to leverage its vast network of 503 stores, which span approximately 20.7 million square feet in retail business area.

Industry insiders suggest this integrated approach is a calculated advantage. By housing pharmacies within high footfall grocery locations, DMart directly tackles two major hurdles faced by both traditional and digital pharmacy players: customer acquisition costs (CAC) and incremental real estate overhead.

Financial Trajectory of the Pharmacy Vertical​

The performance metrics for RHRPL are currently under scrutiny as the pilot program progresses. The company reported revenue of Rs 12.92 crore in FY25, which marks nearly four times growth compared to the previous fiscal year (FY24). However, losses also widened, reaching Rs 2.45 crore from Rs 0.69 crore a year earlier.

The decision to offer a flat 20 percent discount on medicines is central to the strategy. Analysts point out that this move allows DMart to digest significant margin pressure by leveraging its existing infrastructure. One domestic brokerage analyst noted that while traditional DMart operating profit margins stand at 7-8percent, pharmacy offers substantially higher gross margins, often between 25 to 30 percent for branded generics, making the discount potentially sustainable.

Industry Experts Warn of Operational Hurdles​

While the retail trade is keenly watching this entry, several industry leaders caution that transplanting grocery economics into healthcare is complex and fraught with operational challenges. Aggressive, flat discounting in pharmacy retail raises serious long-term sustainability questions.

Rahul Guha, managing director & CEO of Thyrocare and president of operations at API Group, pointed out the extreme pressure a 20 percent margin cut places on operational quality. He stressed that this business model requires meticulous management of high inventory volumes.

The Complexity of Pharmaceutical Inventory Management​

The pharmaceutical sector operates distinctly from the fast-moving consumer goods (FMCG) domain. A standard pharmacy setting must manage an extensive range of medicines to guarantee high fulfilment rates and satisfy diverse local prescription needs.

Industry experts noted that a successful brick-and-mortar store requires maintaining up to 4,000 to 5,000 stock-keeping units (SKUs). Combining the operational demands of such deep inventory cycles with the commitment to absorbing a 20 percent discount margin poses significant challenges for long-term viability. Unlike FMCG, the fragmented pharmaceutical landscape also requires dealing with 50 to 60 individual manufacturers.